[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2134639T3 - Antagonistas del receptor de nk-1 para la prevencion de la inflamacion neurologica en terapia de genes. - Google Patents

Antagonistas del receptor de nk-1 para la prevencion de la inflamacion neurologica en terapia de genes.

Info

Publication number
ES2134639T3
ES2134639T3 ES96931199T ES96931199T ES2134639T3 ES 2134639 T3 ES2134639 T3 ES 2134639T3 ES 96931199 T ES96931199 T ES 96931199T ES 96931199 T ES96931199 T ES 96931199T ES 2134639 T3 ES2134639 T3 ES 2134639T3
Authority
ES
Spain
Prior art keywords
gene therapy
prevention
receptor antagonists
neurological inflammation
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96931199T
Other languages
English (en)
Inventor
Giovanni Piedimonte
Hans J Hess
John A Lowe Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2134639T3 publication Critical patent/ES2134639T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE UN PROCEDIMIENTO PARA EVITAR O TRATAR LA INFLAMACION NEUROGENICA ASOCIADA CON EL USO DE VECTORES VIRICOS EN LA TERAPIA GENICA EN UN MAMIFERO, INCLUYENDO UN HUMANO, MEDIANTE LA ADMINISTRACION AL MAMIFERO DE UN ANTAGONISTA DEL RECEPTOR NK - 1 (POR EJEMPLO, UN ANTAGONISTA DEL RECEPTOR DE LA SUSTANCIA P).
ES96931199T 1995-10-10 1996-10-02 Antagonistas del receptor de nk-1 para la prevencion de la inflamacion neurologica en terapia de genes. Expired - Lifetime ES2134639T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US500295P 1995-10-10 1995-10-10
US634495P 1995-11-07 1995-11-07

Publications (1)

Publication Number Publication Date
ES2134639T3 true ES2134639T3 (es) 1999-10-01

Family

ID=26673771

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96931199T Expired - Lifetime ES2134639T3 (es) 1995-10-10 1996-10-02 Antagonistas del receptor de nk-1 para la prevencion de la inflamacion neurologica en terapia de genes.

Country Status (9)

Country Link
US (1) US6562335B1 (es)
EP (1) EP0854720B1 (es)
JP (1) JP3041051B2 (es)
AT (1) ATE182788T1 (es)
CA (1) CA2228572C (es)
DE (1) DE69603615T2 (es)
ES (1) ES2134639T3 (es)
GR (1) GR3031758T3 (es)
WO (1) WO1997013514A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1067051C (zh) * 1998-06-05 2001-06-13 中国科学院广州化学研究所 一种制备桥环二元酸酐二酯的方法
EP1323713A4 (en) * 2000-09-26 2005-01-26 Tanabe Seiyaku Co 5-PHENYLBENZYLAMINE COMPOUNDS, PROCESS FOR THE PRODUCTION THEREOF AND INTERMEDIATES THEREOF TO SYNTHESIS
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092113T3 (es) 1991-06-20 1996-11-16 Pfizer Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
US6048859A (en) * 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2160462C (en) 1993-05-06 1998-12-15 Timothy P. Burkholder Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
US5703065A (en) * 1993-09-17 1997-12-30 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benyzlaminomethyl piperidines and related compounds
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand

Also Published As

Publication number Publication date
EP0854720B1 (en) 1999-08-04
WO1997013514A1 (en) 1997-04-17
JPH10511119A (ja) 1998-10-27
DE69603615D1 (de) 1999-09-09
CA2228572C (en) 2003-07-22
JP3041051B2 (ja) 2000-05-15
ATE182788T1 (de) 1999-08-15
EP0854720A1 (en) 1998-07-29
DE69603615T2 (de) 2000-02-17
GR3031758T3 (en) 2000-02-29
CA2228572A1 (en) 1997-04-17
US6562335B1 (en) 2003-05-13

Similar Documents

Publication Publication Date Title
MX9708780A (es) Nuevos heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
Roth et al. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest
UA27776C2 (uk) Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
Meriggioli Myasthenia gravis with anti-acetylcholine receptor antibodies
MX9305070A (es) Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
NO980592L (no) Nye opioidpeptider
Lagaudrière‐Gesbert et al. Signaling through the tetraspanin CD82 triggers its association with the cytoskeleton leading to sustained morphological changes and T cell activation
Nevins et al. A comparison of the anticonvulsant effects of competitive and non-competitive antagonist of the N-methyl-d-aspartate receptor
MY118313A (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
TR200805741T2 (tr) At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@
US20090203671A1 (en) Method of treating cancer
ATE170845T1 (de) Plättchenaggregationsinhibitoren
CA2988650A1 (en) Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
Callebaut et al. Inhibition of HIV infection by the cytokine midkine
BR9907847A (pt) Agentes anti-inflamatórios seletivos para glucocorticóides
CA2407895A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
ATE211737T1 (de) Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten
ES2134639T3 (es) Antagonistas del receptor de nk-1 para la prevencion de la inflamacion neurologica en terapia de genes.
DK0659193T3 (da) Blodpladeaggregationsinhibitorer
EE9900275A (et) CD40L-vastaste ühendite terapeutilise manustamise meetodid
ATE235468T1 (de) Plättchenaggregationsinhibitoren
US8507438B2 (en) Compositions and methods for the treatment of neurologic and psychiatric conditions
Turski et al. Anticonvulsant action of stereoisomers of γ-glutamylaminomethylsulphonic acid in mice
Takeuchi et al. Role of prostaglandin E receptor subtypes in gastroduodenal HCO3-secretion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 854720

Country of ref document: ES